Cabaletta Approach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cabaletta approach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cabaletta Approach Today - Breaking & Trending Today

Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial



PHILADELPHIA, May 03, 2021 (GLOBE NEWSWIRE) Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced acute safety data from the first dose cohort of the ongoing DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV).
We are encouraged by the acute safety profile of DSG3-CAART in this initial low dose cohort. In the first cohort of three patients dosed with DSG3-CAART, there were no clinically relevant adverse events, including cytokine release syndrome or neurotoxicity, during the 8-day acute safety window, which we expect is the period with highest probability of observing treatment-related toxicities. In addition, no dose-limiting toxicities or clinically relevant adverse events were observed in the two patients who have completed mo ....

United States , Davidj Chang , Anup Marda , Sarah Mccabe , Exchange Commission , Cabaletta Bio Inc , Stern Investor Relations Inc , Chief Medical Officer , Autoantibody Receptor , Cabaletta Approach , Fast Track Designation , Private Securities Litigation Reform Act , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , அனுப்பி மார்டா , சாரா ம்க்கேப் , பரிமாற்றம் தரகு , கடுமையான முதலீட்டாளர் உறவுகள் இன்க் , தலைமை மருத்துவ அதிகாரி , வேகமாக டிராக் பதவி , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , முதலீட்டாளர் உறவுகள் ,